Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
An aptamer-mRNA conjugate is provided. The aptamer-mRNA conjugate may include an aptamer component that binds a membrane associated protein on a target cell and an mRNA component that is expressed by the target cell.
1. An aptamer-mRNA conjugate comprising:
an aptamer component that binds a membrane associated protein on a target cell; and
an mRNA component that is expressed by the target cell, wherein the mRNA component is an mRNA molecule.
2. The aptamer-mRNA conjugate of claim 1 , wherein the membrane associated protein is CD4, CD19, DC-SIGN/CD209, HIV envelope glycoprotein gp120, CCR5, EGFR/ErbB1, EGFR2/ErbB2/HER2, EGFR3/ErbB3, EGFR4/ErbB4, EGFRvIII, Transferrin Receptor, PSMA, VEGF, VEGF-2, CD25, CD11a, CD33, CD20, CD3, CD52, CEA, TAG-72, LDL receptor, insulin receptor, megalin receptor, LRP, mannose receptor, P63/CKAP4 receptor, arrestin, ASGP, CCK-B, HGFR, RON receptor, FGFR, ILR, AFP, CA125/MUC16, PDGFR, stem cell factor receptor, colony stimulating factor-1 receptor, integrins, TLR, BCR or BAFF-R.
3. The aptamer-mRNA conjugate of claim 1 , wherein the mRNA component is a therapeutic agent.
4. The mRNA component of claim 3 , wherein the therapeutic agent is a cytotoxin, an enzyme, or an antibody or functional fragment thereof.
5. The aptamer-mRNA conjugate of claim 1 , wherein the mRNA component is a fluorescent or bioluminescent protein.
6. An aptamer-mRNA conjugate comprising:
an aptamer component that binds a membrane associated protein on a target cell, wherein the aptamer component comprises SEQ ID NO:1 or SEQ ID NO:2, and
an mRNA component that is expressed by the target cell.
7. The aptamer-mRNA conjugate of claim 6 , wherein the mRNA component is a fluorescent or bioluminescent protein.